Y
Yin Yang
Researcher at Seattle Genetics
Publications - 19
Citations - 1220
Yin Yang is an academic researcher from Seattle Genetics. The author has contributed to research in topics: Brentuximab vedotin & Indolent Non-Hodgkin Lymphoma. The author has an hindex of 9, co-authored 19 publications receiving 1064 citations.
Papers
More filters
Journal ArticleDOI
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro,Ranjana H. Advani,Pauline Brice,Nancy L. Bartlett,Joseph D. Rosenblatt,Timothy M Illidge,Jeffrey Matous,Radhakrishnan Ramchandren,Michelle A. Fanale,Joseph M. Connors,Yin Yang,Eric L. Sievers,Dana A. Kennedy,Andrei R. Shustov +13 more
TL;DR: Targeted therapy with this CD30-directed antibody-drug conjugate brentuximab vedotin may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy.
Journal ArticleDOI
Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Caron A. Jacobson,Julio C. Chavez,Alison R. Sehgal,Basem M. William,Javier Munoz,Gilles Salles,Pashna N. Munshi,Carla Casulo,David G. Maloney,Sven de Vos,Ran Reshef,Lori A. Leslie,Ibrahim Yakoub-Agha,Olalekan O. Oluwole,Henry C.H. Fung,Joseph D. Rosenblatt,John M. Rossi,Lovely Goyal,Vicki Plaks,Yin Yang,Jennifer Lee,Wayne R. Godfrey,Remus Vezan,Mauro P. Avanzi,Sattva S. Neelapu +24 more
TL;DR: Axi-cel autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy is approved for the treatment of R/R large B cell lymphoma after ≥ 2 lines of systemic therapy and was comparable across key risk groups analyzed by FLIPI, POD24, GELF, refractory status, and prior lines of therapy.
Journal ArticleDOI
Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
Caron A. Jacobson,Julio C. Chavez,Alison R. Sehgal,Basem M. William,Javier Munoz,Gilles Salles,Carla Casulo,Pashna N. Munshi,David G. Maloney,Sven de Vos,Ran Reshef,Lori A. Leslie,Ibrahim Yakoub-Agha,Olalekan O. Oluwole,Henry C. Fung,Vicki Plaks,Yin Yang,Jennifer Lee,Mauro P. Avanzi,Sattva S. Neelapu +19 more
TL;DR: This data indicates that conventional chemotherapy for advanced stage follicular lymphoma and marginal zone lymphoma requires at least two booster doses of chemotherapy to be effective and safe.
Journal ArticleDOI
A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas
Nancy L. Bartlett,Jeff P. Sharman,Yasuhiro Oki,Ranjana H. Advani,Celeste M. Bello,Jane N. Winter,Yin Yang,Dana A. Kennedy,Eric D. Jacobsen +8 more
TL;DR: This subset analysis presents interim data for patients with relapsed/refractory Bcell neoplasms with variable CD30 expression as assessed by the Revised Response Criteria for Malignant Lymphoma.
Journal ArticleDOI
Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)
Sattva S. Neelapu,Michael Dickinson,Matthew L. Ulrickson,Olalekan O. Oluwole,Alex F. Herrera,Catherine Thieblemont,Chaitra S. Ujjani,Yi Lin,Peter A. Riedell,Natasha Kekre,Sven de Vos,Yin Yang,Francesca Milletti,Lovely Goyal,Jun Kawashima,Julio C. Chavez +15 more
TL;DR: Interim efficacy, safety, and pharmacokinetics results from ZUMA-12, a Phase 2, multicenter, open-label, single-arm study of axi-cel as part of first-line therapy in pts with high-risk LBCL, are presented.